527
Views
2
CrossRef citations to date
0
Altmetric
Short Communications

Marked and prolonged serotonin toxicity in a tramadol-poisoned patient with a pharmacokinetic study

, , , , , , ORCID Icon & show all
Pages 382-385 | Received 28 Apr 2021, Accepted 09 Jul 2021, Published online: 21 Jul 2021

References

  • Doostmohammadi M, Rahimi HR. ADME and toxicity considerations for tramadol: from basic research to clinical implications. Expert Opin Drug Metab Toxicol. 2020;16(7):627–640.
  • Ryan NM, Isbister GK. Tramadol overdose causes seizures and respiratory depression but serotonin toxicity appears unlikely. Clin Toxicol. 2015;53(6):545–550.
  • Mégarbane B, Lagard C, Chevillard L. Tramadol: distinguishing the pathophysiology of serotonin syndrome and seizures. Am J Med. 2018;131(11):e487.
  • Ahmadimanesh M, Naeini MB, Rouini MR, et al. Assessment of tramadol pharmacokinetics in correlation with CYP2D6 and clinical symptoms. Drug Metab Pers Ther. 2020;35(2).
  • Sternbach H. The serotonin syndrome. Am J Psychiatry. 1991;148(6):705–713.
  • Dunkley EJ, Isbister GK, Sibbritt D, et al. The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity. QJM. 2003;96(9):635–642.
  • Lagard C, Chevillard L, Malissin I, et al. Mechanisms of tramadol-related neurotoxicity in the rat: does diazepam/tramadol combination play a worsening role in overdose? Toxicol Appl Pharmacol. 2016;310:108–119.
  • Hagelberg NM, Saarikoski T, Saari TI, et al. Ticlopidine inhibits both O-demethylation and renal clearance of tramadol, increasing the exposure to it, but itraconazole has no marked effect on the ticlopidine-tramadol interaction. Eur J Clin Pharmacol. 2013;69(4):867–875.
  • Tolledo EC, Miksys S, Gonzalez FJ, et al. Propranolol is a mechanism-based inhibitor of CYP2D and CYP2D6 in humanized CYP2D6-transgenic mice: effects on activity and drug responses. Br J Pharmacol. 2020;177(3):701–712.
  • Bertelsen KM, Venkatakrishnan K, Von Moltke LL, et al. Apparent mechanism-based inhibition of human CYP2D6 in vitro by paroxetine: comparison with fluoxetine and quinidine. Drug Metab Dispos. 2003;31(3):289–293.
  • Degraeve AL, Moudio S, Haufroid V, et al. Predictors of tacrolimus pharmacokinetic variability: current evidences and future perspectives. Expert Opin Drug Metab Toxicol. 2020;16(9):769–782.
  • Kuypers DR, Verleden G, Naesens M, et al. Drug interaction between mycophenolate mofetil and rifampin: possible induction of uridine diphosphate-glucuronosyltransferase. Clin Pharmacol Ther. 2005;78(1):81–88.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.